Vistagen Presents Exploratory Data on PH80's Effects on Menopausal Hot Flashes
ByAinvest
Wednesday, Nov 26, 2025 8:31 am ET1min read
VTGN--
Vistagen presented exploratory data at The Menopause Society 2025 Annual Meeting demonstrating PH80's potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms due to menopause. PH80 reduced autonomic nervous system activity after intranasal administration and was not absorbed into the bloodstream in humans. The research showed PH80's rapidly-acting, neurocircuitry-focused effects without binding to steroid hormone receptors or neurotransmitter receptors associated with abuse.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet